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administered via Respimat Soft Mist Inhaler or
HandiHaler in COPD patientsWe want to thank Dr Garcı´a Arieta for his interest in our
comparative study of tiotropium administered via Respimat
Soft Mist Inhaler (Rmt) or via the HandiHaler (HH) con-
ducted in COPD patients.1 We agree that an inhalation
product comparison is a difficult task and that the present
study1 would not suffice as sole evidence to establish
comparability in efficacy, safety and systemic exposure and
to support a product registration based on therapeutic
equivalence to an originator product.
However, this was neither intended nor stated in the
article1: Our core conclusions were (1) superiority of all
tiotropium doses and formulations over placebo, (2) non-
inferiority of both doses of tiotropium Rmt to the HH
formulation and (3) similar systemic exposure. (4) We are
not aware of general safety comparisons between formu-
lations in the literature that are fully powered. This would
be an extremely difficult endeavour. However, our study
especially mentions similar and low incidence of dry mouth
following Rmt 5 mg and HH 18 mg, which can be regarded
a sensitive marker for anticholinergic effects, which is
informative also in smaller studies.
To be noted, tiotropium Rmt 5 mg was profiled by a full
stand-alone development programme beyond the study
discussed here consisting of a chronic dose-ranging study,2
and four Phase III studies of 12e48 weeks duration including
more than 3000 patients with COPD. Dose selection for
tiotropium Rmt was based on the totality of data, and
eventually on comparison of efficacy and safety in two
large 48 week placebo controlled studies including two
doses of tiotropium Rmt.
Our study provides undisputed evidence that the 5 mg dose
of tiotropiumRmt, selectedbasedonPhase III-studyevidence,
is at least non-inferior to tiotropium HH. The observed
difference of 0.029 L in favour of the tiotropium Rmt was
statistically significant, but is probably not clinically relevant.
Our study was not designed as a formal bioequivalence
study and respected limitations in the number of blood
samples that may be taken in a therapeutic trial withDOI of original article: 10.1016/j.rmed.2009.02.017.
0954-6111/$ - see front matter ª 2009 Elsevier Ltd. All rights reserved
doi:10.1016/j.rmed.2009.06.019patients. Formal bioequivalence criteria are not estab-
lished for inhalation products anyway. As described,1 the
geometric mean renal excretion value, the plasma
concentration at 10 min post-dose and the area under the
plasma concentration-time curve over 6 h were numerically
slightly higher following inhalation of 5 mg via the Rmt
inhaler compared to tiotropium 18 mg via the HH, but
evaluation of the intra-individual comparison between
treatments did not suggest a systematic difference in
systemic exposure between the formulations.
In conclusion, our study positions an alternative inno-
vative formulation of tiotropium by Rmt as non-inferior in
efficacy and similar in exposure compared to the estab-
lished HH formulation.
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